Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study.

about

Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study.

Item

http://www.wikidata.org/entity/Q47871089

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Dapagliflozin and Empagliflozi ...... spective, Observational Study.

@en

Dapagliflozin and Empagliflozi ...... spective, Observational Study.

@nl

type

Item

label

Dapagliflozin and Empagliflozi ...... spective, Observational Study.

@en

Dapagliflozin and Empagliflozi ...... spective, Observational Study.

@nl

prefLabel

Dapagliflozin and Empagliflozi ...... spective, Observational Study.

@en

Dapagliflozin and Empagliflozi ...... spective, Observational Study.

@nl

P1476

Dapagliflozin and Empagliflozi ...... spective, Observational Study.

@en

P2093

Carol Ho Yi Fong

http://www.w3.org/2001/XMLSchema#string

Karen Siu Ling Lam

http://www.w3.org/2001/XMLSchema#string

Kathryn Tan

http://www.w3.org/2001/XMLSchema#string

Man Yi Yeung

http://www.w3.org/2001/XMLSchema#string

Paul Chi Ho Lee

http://www.w3.org/2001/XMLSchema#string

Wing Sun Chow

http://www.w3.org/2001/XMLSchema#string

Yu Cho Woo

http://www.w3.org/2001/XMLSchema#string

Yunjuan Gu

http://www.w3.org/2001/XMLSchema#string

P2860

A new equation to estimate glomerular filtration rate

Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action.

Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study.

The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.

Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease.

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α2-Glycoprotein Levels in Patients with Type 2 Diabetes.

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cot

P2888

s13300-017-0355-3

P304

285-295

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13300-017-0355-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29322486

http://www.w3.org/2001/XMLSchema#string

P932

5801241

http://www.w3.org/2001/XMLSchema#string